التداخل بين ألموتريبتان وسوماتريبتان ونابروكسين

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)].

Recent (within 24 hours) use of another 5-HT1 agonist (e.g., another triptan) or of ergotamine-containing medication.

Intervention: Because these effects may be additive, coadministration of sumatriptan and naproxen sodium tablets and other 5 HT 1 agonists (e.g., triptans) within 24 hours of each other is contraindicated.

Do not use almotriptan tablets within 24 hours of an ergotamine-containing, or ergot-type medication, or of another 5-HT 1 agonist, e.g., another triptan ( 4.5 , 4.6 )

Life-threatening disturbances of cardiac rhythm and death have been reported within a few hours following the administration of other triptans.

Cerebrovascular Events and Fatalities Cerebral hemorrhage, subarachnoid hemorrhage, stroke, and other cerebrovascular events have been reported in patients treated with other triptans and some events have resulted in fatalities.

Do not use almotriptan tablets and other 5-HT 1 agonists (e.g., triptans) within 24 hours of each other ( 4.6 , 7.2 )

Increases in Blood Pressure As with other triptans, significant elevations in systemic blood pressure have been reported on rare occasions with almotriptan tablets use in patients with and without a history of hypertension; very rarely these increases in blood pressure have been associated with significant clinical events.